Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need.
Business Model:
Revenue: $0
Employees: 1-10
Rankings
Industries / Tags:
Detailed Palisade Bio Information
Geographic Data
Address:
City: Germantown
State: Maryland
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$2M
Raised Total:$35M
Social
Metrics
1,789,181Website Global Rank
4,753Website Monthly Traffic
Twitter Followers
Description
Palisade Bio is a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need. Seneca is in the process of finding and acquiring new assets, promising sciences, and technologies that will provide meaningful therapies for patients.
Contact Phone:
Contact Email:
Palisade Bio went public on 12/22/2006 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
12/22/2006
Ticker Symbol:
PALI
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2022 | Post-IPO Equity | $2M | 8/2021 | Post-IPO Equity | 1 | $5.2M |
Yuma Regional Medical Center Yuma Regional Medical Center |
5/2020 | Post-IPO Equity | $5M | 1/2023 | Post-IPO Equity | $4.9M | 8/2022 | Post-IPO Equity | $13.8M | 12/2020 | Post-IPO Equity | 1 | $22.5M |
Altium Capital Altium Capital Altium Capital Altium Capital |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 12/2020 | Leading BioSciences, Inc. |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
